Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.According to data presented by AstraZeneca at the San Antonio Breast Cancer Symposium, its drug Arimidex improved progression free survival when combined with Genentech's Herceptin.
Subscribe to our email newsletter
A study revealed that particpants who received Arimidex and Herceptin in combination demonstrated an extended median progression-free survival of 4.8 months, representing an extension of 2.4 months over patients receiving Arimidex alone.
“The combination of Arimidex plus Herceptin suggests a significant improvement in progression-free survival for this unique patient population, whose disease can be particularly aggressive,” said Dr Joseph Purvis, AstraZeneca, executive director, Clinical Research, Oncology.
In women receiving Arimidex plus Herceptin, time to tumor progression was doubled and median overall survival prolonged by 4.6 months compared to women receiving Arimidex alone.
AstraZeneca said that while patients who participated in this study continue to be followed for any side effects, overall safety data in both arms of the trial were consistent with the known safety profile of each of the drugs in the advanced breast cancer setting.